Synthesis and biological evaluation of novel pyrido [2, 3-b] pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines
L Kékesi, A Sipos, G Németh, J Pató, N Breza… - Bioorganic & medicinal …, 2013 - Elsevier
A series of novel pyrido [2, 3-b] pyrazines were synthesized as potential antitumor agents for
erlotinib-resistant tumors. Known signal inhibitor compounds from our Nested Chemical …
erlotinib-resistant tumors. Known signal inhibitor compounds from our Nested Chemical …
肿瘤分子靶向治疗药物的应用进展
詹琼 - 上海医药, 2011 - cqvip.com
分子靶向治疗作为肿瘤治疗的新手段, 正以其低毒, 副反应和高治疗效果成为肿瘤治疗研究的
热点. 按作用靶点以及药物的性质, 分子靶向药物可分为数类, 主要包括以EGFR 为靶点的药物 …
热点. 按作用靶点以及药物的性质, 分子靶向药物可分为数类, 主要包括以EGFR 为靶点的药物 …
非小细胞肺癌患者血清CEA 水平与EGFR-TKI 疗效的关系
李醒亚， 成媛， 刘杰， 申淑景， 贾永旭 - 中国癌症杂志, 2011 - cqvip.com
背景与目的: 靶向治疗药物表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor
receptor tyrosine kinase inhibitors, EGFR-TKI) 在晚期非小细胞肺癌(non-small cell lung …
receptor tyrosine kinase inhibitors, EGFR-TKI) 在晚期非小细胞肺癌(non-small cell lung …
Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: a case …
L Fang, J He, J Xia, L Dong, X Zhang… - Oncology …, 2017 - spandidos-publications.com
First-generation epithelial growth factor receptor tyrosine kinase inhibitors (EGFR‑TKIs) have
markedly improved the treatment of non-small cell lung cancer (non‑SCLC) with EGFR …
markedly improved the treatment of non-small cell lung cancer (non‑SCLC) with EGFR …
Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
CH Chang, CH Lee, JC Ko, LY Chang… - Cancer …, 2017 - Wiley Online Library
Among treatment modalities for lung cancer, the most promising therapy is the use of
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and …
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity
K Yonesaka, T Suzumura, H Tsukuda… - Anticancer …, 2014 - ar.iiarjournals.org
Aim: To evaluate the tolerability and efficacy of erlotinib treatment in advanced non-small
cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity …
cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity …
[HTML][HTML] Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Non–Small-Cell Lung Cancer
CY Wang, TT Chao, WT Tai, FY Chang, WP Su… - Journal of Thoracic …, 2014 - Elsevier
Introduction: Targeting signal transducer and activator of transcription 3 (STAT3), a
transcription factor that modulates survival-directed transcription, is often persistently …
transcription factor that modulates survival-directed transcription, is often persistently …
[HTML][HTML] Targeted therapy for leptomeningeal metastases in non-small cell lung cancer–Changing treatment paradigms
BK Shah, I Pak, N Budhathoki… - Chinese Journal of Cancer …, 2017 - ncbi.nlm.nih.gov
Leptomeningeal metastasis is an uncommon but serious complication in patients with
advanced cancers. Leptomeningeal metastasis is diagnosed in approximately 5% of the …
advanced cancers. Leptomeningeal metastasis is diagnosed in approximately 5% of the …
[DOC][DOC] NGHIÊN CỨU ĐẶC ĐIỂM ĐỘT BIẾN GEN EGFR VÀ MỐI LIÊN QUAN VỚI LÂM SÀNG, CẬN LÂM SÀNG Ở BỆNH NHÂN UNG THƯ PHỔI MÔ TUYẾN
NTHỊLAN ANH - 2017 - lib.yhn.edu.vn
BỘ GIÁO DỤC VÀ ĐÀO TẠO BỘ QUỐC PHÒNG HỌC VIỆN QUÂN Y NGUYỄN THỊ LAN ANH
Nghiên cứu Đặc điểm đột biến gen EGFR VÀ MỐI LIÊN QUAN VỚI LÂM SÀNG, CẬN LÂM …
Nghiên cứu Đặc điểm đột biến gen EGFR VÀ MỐI LIÊN QUAN VỚI LÂM SÀNG, CẬN LÂM …
晚期NSCLC 患者外周血中EGFR 突变预测EGFR TKIs 一线治疗的疗效的观察
王童非， 李晓惠， 张菊， 张贺龙 - 现代肿瘤医学, 2011 - cqvip.com
目的: 检测NSCLC 患者外周血EGFR 突变情况, 预测EGFR TKIs 作为治疗晚期NSCLC
的一线疗法的疗效. 方法: 应用荧光偏振(TDI-FP) 法检测51 例晚期非小细胞肺癌患者外周血 …
的一线疗法的疗效. 方法: 应用荧光偏振(TDI-FP) 法检测51 例晚期非小细胞肺癌患者外周血 …